# Anbogen Therapeutics

Source: https://onco.cc/companies/anbogen-therapeutics/  
OnCo record `anbogen-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anbogen Therapeutics is a Taiwan-based biotechnology company that leads 2 cancer trials in OnCo, testing ABT-101 and ABT-301 in colorectal cancer and non-small-cell lung cancer.

## Summary

Anbogen Therapeutics is a precision oncology company in Taipei developing targeted cancer therapies. Its candidates include ABT-101, licensed from Taiwan's National Health Research Institutes, and ABT-301, licensed from Taipei Medical University. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07244705 (phase 1/2, A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advance...) and NCT05532696 (phase 1/2, Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: 安邦生技
- Tags: ctgov-sponsor
- HQ: Taipei
- Type: biotech
- Website: https://anbogen.com/

## Sources

- Official website: https://anbogen.com/
- ClinicalTrials.gov: trials led by Anbogen Therapeutics: https://clinicaltrials.gov/search?lead=Anbogen%20Therapeutics%2C%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [ABT-301](https://onco.cc/drugs/abt-301/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- trials: [A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC](https://onco.cc/trials/nct07244705/), [Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients](https://onco.cc/trials/nct05532696/)

---
JSON: https://onco.cc/api/v1/entities/anbogen-therapeutics.json